Self-administered pain therapy by way of a patient-controlled analgesia (PCA) device in Trevena Inc.'s phase IIb trial let TRV130's attention-getting safety profile emerge, and Wall Street didn't miss the significance, pushing the shares (NASDAQ:TRVN) by the end of the day to $9.05, up $3.05, or 50.8 percent.
"We saw what we expected, and we do believe it was because of the way the drug was given," CEO Maxine Gowen told BioWorld Today. "That was really the whole theoretical basis for starting the program."
The biased mu opioid receptor ligand/opioid receptor modulator was tested in moderate to severe acute postoperative pain after abdominoplasty (otherwise known as a tummy tuck), hitting the primary endpoint of statistically significant reduction in pain over 24 hours. The drug proved superior to morphine in pre-specified secondary measures